Literature DB >> 2122930

Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.

M Chiron1, J P Jaffrezou, P Carayon, C Bordier, F Roubinet, C Xavier, M Brandely, G Laurent.   

Abstract

In order to evaluate the impact of induction and increase target antigen expression on immunotoxin potency, we measured the potentiating effect of recombinant immune interferon-gamma (rIFN-gamma) on the cytotoxicity of an anti HLA-DR ricin A-chain immunotoxin (2G5 RTA-IT) on the myeloid cell line ML-3. After 48 h of incubation with rIFN-gamma (500 U/ml) the percentage of 2G5-positive cells increased from 40% to 79%, and the 2G5 mean density was enhanced by 10-fold (11,000 versus 110,000 molecules/cell). Concurrently, rIFN-gamma pretreatment induced a dramatic improvement of 2G5 RTA-IT dose-effect cytotoxicity, as well as immunotoxin cytotoxicity kinetics. When 2G5 RTA-IT was used at the optimal dose of 10(-8)M (the maximum dose which avoided non-specific ricin A-chain cytotoxicity), the immunotoxin-induced cell kill increased with the percentage of DR-positive ML-3 cells according to a similar linear-logarithmic function of rIFN-gamma concentration. Moreover, in the same range of rIFN-gamma concentrations, the killing values and the percentage of DR-positive ML-3 cells were similar if not identical. These findings imply that the enhancement of 2G5 RTA-IT cytotoxicity by rIFN-gamma is mainly related to the rIFN-gamma 2G5 antigen induction on HLA-DR negative cells when immunotoxin was used at 10(-8) M. Furthermore, 2G5 RTA-IT dose-effect cytotoxicity on DR-expressing ML-3 cells, when used at lower concentrations, was also increased by rIFN-gamma in a dose-dependent manner. This result suggests that for immunotoxin concentrations close to the limiting membrane saturation dose (10(-10)M), rIFN-gamma may not solely act by inducing HLA-DR expression on DR-negative ML-3 subpopulation but also by increasing individual cellular DR density on DR expressing ML-3 cells. Finally, our study showed that immunotoxin potency on malignant cell populations which display an heterogeneous antigen expression, could be greatly improved by the use of rIFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122930      PMCID: PMC1535130          DOI: 10.1111/j.1365-2249.1990.tb05429.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.

Authors:  M Herlyn; D Guerry; H Koprowski
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

2.  Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions.

Authors:  D Taramelli; G Fossati; A Mazzocchi; D Delia; S Ferrone; G Parmiani
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

3.  Heterogeneity of the induction of HLA-DR expression by human immune interferon on glioma cell lines and their clones.

Authors:  V Piguet; S Carrel; A C Diserens; J P Mach; N de Tribolet
Journal:  J Natl Cancer Inst       Date:  1986-02       Impact factor: 13.506

4.  Cytofluorometric quantification of cell-surface antigens by indirect immunofluorescence using monoclonal antibodies.

Authors:  P Poncelet; P Carayon
Journal:  J Immunol Methods       Date:  1985-12-17       Impact factor: 2.303

5.  Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.

Authors:  P Casellas; B J Bourrie; P Gros; F K Jansen
Journal:  J Biol Chem       Date:  1984-08-10       Impact factor: 5.157

6.  Biochemical aspects of immunotoxin preparation.

Authors:  O Gros; P Gros; F K Jansen; H Vidal
Journal:  J Immunol Methods       Date:  1985-08-02       Impact factor: 2.303

7.  Optimal elimination of leukemic T cells from human bone marrow with T101-ricin A-chain immunotoxin.

Authors:  P Casellas; X Canat; A A Fauser; O Gros; G Laurent; P Poncelet; F K Jansen
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

8.  Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment.

Authors:  J W Greiner; P H Hand; P Noguchi; P B Fisher; S Pestka; J Schlom
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

9.  Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens.

Authors:  S Carrel; A Schmidt-Kessen; L Giuffrè
Journal:  Eur J Immunol       Date:  1985-02       Impact factor: 5.532

10.  Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.

Authors:  F M Uckun; K J Gajl-Peczalska; J H Kersey; L L Houston; D A Vallera
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

View more
  4 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule.

Authors:  E J Derbyshire; R A Stahel; E J Wawrzynczak
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 3.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.

Authors:  Jenny Fitting; Tobias Blume; Andre Ten Haaf; Wolfgang Blau; Stefan Gattenlöhner; Mehmet Kemal Tur; Stefan Barth
Journal:  MAbs       Date:  2015       Impact factor: 6.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.